News | Prostate Cancer | November 02, 2015

First Results Reported for Prostate Cancer Targeted Brachytherapy Using CivaString

Palladium-based source offers positive outcomes with more highly targeted radiation

CivaTech Oncology, CivaString, prostate brachytherapy, 103Pd radiation source, ASTRO 2015

Image courtesy of Business Wire

November 2, 2015 — CivaTech Oncology Inc. has developed a new U.S. Food and Drug Administration (FDA)-cleared radiation source. The CivaString source features 103Pd (palladium) along the full length of the device, which is contained using low-Z polymers. Low-dose-rate brachytherapy historically relies on a loose or stranded isotope whose dosimetry is characterized as point sources. A polymer-encapsulated 103Pd source with a unique linear radioactive distribution provides a useful refinement for prostate brachytherapy.

An abstract and poster titled “First Report of a New 103Pd Line Source for Prostate Brachytherapy” presenting results from the first 14 patients in an ongoing clinical study was submitted and accepted at the American Society for Radiation Oncology (ASTRO) 2015 conference in San Antonio, and published in ASTRO’s International Journal of Radiation Oncology. Radiation oncologists David Beyer, M.D., and Richard Stock, M.D., implanted patients in Arizona and New York.

The abstract concluded: “An initial experience with this new line source is presented. Excellent implants across a range of gland sizes were accomplished. Prostate volume changes were minimal suggesting minimal swelling using the chosen needles and ‘strings.’ Good dosimetry is achieved for both preplans and eventual implants. Using a line source, the number of needles required per patient is less than that reported with standard brachytherapy sources. Intraoperative ease of use is good.”

This study is ongoing with 26 total patients and is expected to conclude at the end of 2015, at which time a full report will be published. Additionally a five-year, 150-patient registry has begun to fully demonstrate how the advanced polymer technology benefits patients when used to treat prostate cancer.

For more information: www.civatechoncology.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.